Why Dental’s Biggest Problems Keep Getting Solved by the Wrong People

There is a pattern I have watched repeat itself across 25 years in the dental sector.

A problem emerges – associate pay reconciliation, acquisition due diligence, offshore staffing, cash flow forecasting, compliance reporting. Someone builds a solution. The solution is technically competent. And yet, six months later, the problem persists in a slightly different form. The practice owner is still frustrated. The finance director is still doing manual work. The PE investor is still finding surprises in the numbers after close.

I used to think this was a failure of execution but I no longer believe that.

I think it is a failure of perspective.

The Specialist Trap

The dental sector has attracted a lot of very good specialists. Excellent accountants who understand the tax treatment of goodwill. Sophisticated software companies that have mapped every clinical workflow. Capable offshore providers who can staff a bookkeeping function at a fraction of UK cost. Experienced brokers who know how to structure a practice acquisition.

Each of these specialists is genuinely skilled within their domain. The problem is that dental business problems do not live within domains. They live at the boundaries between them.

Take associate pay – the most operationally painful process in any multi-site dental group. On the surface it looks like a payroll problem. Build a payroll tool, problem solved. But anyone who has actually run a dental practice knows that associate pay sits at the intersection of clinical data (UDA completions, patient charges, plan mix), contractual logic (split percentages, recall fees, lab deductions), accounting treatment (self-employed versus employed, IR35 implications), and software integration (PMS, payroll, Xero). A payroll specialist sees the output. They do not see the four upstream systems feeding it. So the tool they build handles the final calculation and breaks on everything that precedes it.

This is not an isolated example. It is the structural condition of the entire sector.

What I Learned from Investment Banking

Before founding Samera in 2002, I trained at PwC and worked as a VP at Bank of America. Investment banking is, at its core, a discipline about seeing the whole system – understanding how capital, operations, risk and human behaviour interact, and where the real value and the real danger actually sit.

When I moved into the dental sector, I carried that lens with me. And what I saw was an industry being served by people who understood their own corner of it extremely well, but who had never been forced to see how the corners connected.

The dentist who became a practice owner had no framework for reading a balance sheet. The accountant managing that practice had never sat in a clinical meeting and understood why UDA targets were missed. The software company building the PMS had never tried to reconcile an associate’s pay at month end. The offshore team processing the bookkeeping had never understood the specific regulatory context of NHS versus private versus mixed practice.

Everyone was competent. Nobody had the full picture. And so the problems persisted.

The Medici Effect – and Why It Explains What We Built

There is a concept in innovation theory called the Medici Effect. The Medici family of Renaissance Florence funded artists, scientists, architects and philosophers to work in the same city. When these disciplines collided – when a sculptor talked to a mathematician, when an architect borrowed from a botanist – something extraordinary happened. The intersections produced the Renaissance.

Frans Johansson, who named the effect, made a distinction that has stayed with me. He separated directional innovation – going deeper within a single field, incremental improvement, diminishing returns – from intersectional innovation, where ideas from unrelated disciplines collide to create something genuinely new. Directional innovation gets commoditised. Intersectional innovation builds moats.

The dental sector is full of directional innovation. Better PMS software. Faster bookkeeping. Cheaper offshore staff. Each improvement is real. None of them solve the underlying problem, because the underlying problem is not a single-domain problem.

What I have spent 25 years building – sometimes consciously, sometimes by necessity – is an organisation that lives permanently at the intersection. Not deeper in one domain, but wider across all of them simultaneously.

Building the Ecosystem Deliberately

Samera started as an accounting firm focused exclusively on dentistry. That sector depth meant we understood the numbers better than any generalist accountant. But over time it became clear that the accounting problems we were solving were symptoms of upstream operational problems. So we built the capability to address those too.

The offshore delivery centre in India was not a cost play. It was a recognition that the talent required to support growing dental groups at scale did not exist in sufficient quantity in the UK – and that building a genuinely high-quality remote team required both the operational knowledge to train them in dental-specific processes and the cultural fluency to manage across geographies effectively. Twenty-five years of relationships and context made that possible. A GCC provider with no sector history cannot replicate it.

Samera.ai – our intelligence platform integrating directly with Dentally and Xero (more integrations are coming) – did not emerge from a product roadmap. It emerged from watching the same reconciliation problem cause the same disputes and inefficiencies across hundreds of client practices, and realising that no existing software was solving it because no existing software company had lived inside the problem long enough to understand it fully. Associate pay is where it starts. The intelligence layer – M&A valuation, CFO intelligence, cash flow, KPI reporting, daily actions – is where it leads.

Samera Finance, our FCA-regulated commercial finance brokerage, exists because we kept watching clients navigate acquisitions without access to the right capital structure. Understanding the deal from the accounting side and the operational side meant we could see financing gaps that a standalone broker would never identify.

Each piece was built because the intersection demanded it. The ecosystem was not designed. It was grown from 25 years of being forced to see the connections that specialists miss.

The Intersection Is the Proof

I own a dental group – The Neem Tree Dental Group, with practices in Wandsworth and Esher, co-founded with my wife Smita. This matters not as a footnote but as a proof point. Every piece of software we build, every process we automate, every offshore hire we make – we test it first in our own business. We are not advisors standing outside the system describing it. We are operators inside it, building tools we use ourselves.

Recently, we have secured a partnership with a leading Indian Technical University, Bannari Amman Institute of Technology in Tamil Nadu, to train AI engineering students in finance and accounting. The offshore delivery centre and the AI platform are not separate businesses – they are the same business, viewed from different angles. The engineers who build Samera.ai are trained in the domain context that makes the software actually work. That combination does not exist anywhere else in this sector.

We are now expanding into Europe – entering PE-backed dental groups bringing the same offshore delivery, intelligence software and financial advisory capability that we built for the UK market. The intersection travels. The problems are the same. The solutions require the same breadth of perspective.

What This Means in Practice

I am not arguing that specialists have no value. They have enormous value within their domains. What I am arguing is that the integrator – the person or firm that can hold the full system in mind, that can translate between the clinical and the financial and the operational and the technological – is the rarest and most valuable asset a scaling dental business can access.

For PE investors conducting due diligence on a dental platform, the questions that matter are not just about EBITDA multiples and site-level profitability. They are about whether the operational infrastructure can support the growth thesis – whether the associate pay processes scale, whether the offshore capability is genuinely built or just outsourced, whether the technology layer creates margin expansion or just replicates manual processes digitally. Samera can sit alongside a PE firm across all of those questions simultaneously. No single-discipline adviser can.

For DSO finance directors managing groups of 20, 50 or 100 sites, the question is not just whether the books are accurate. It is whether the firm managing those books understands the clinical and operational context well enough to flag what the numbers are actually telling you – and whether the software they use was built by people who understand dental workflows or by engineers who have never met a dental nurse.

For independent dentists preparing to scale, the question is whether the advisors around the table understand not just the transaction but the business they are building – the culture, the staffing model, the associate relationships, the patient mix – and can structure a deal that serves the long-term vision, not just the immediate tax position.

The answers to all of these questions require someone who has sat in enough of the seats to understand how they connect. That is what 25 years at the intersection produces.

The 25-Year View

I have run 30 Setting Up in Practice events. I have advised on hundreds of acquisitions. I have watched practices that were financially well-structured fail because of operational decisions that an accountant would never have flagged. I have watched software solve the wrong problem with extraordinary technical precision. I have watched offshore teams process numbers they did not understand, because nobody trained them in the context behind the figures.

The sector has matured significantly. The problems have become more complex. The capital involved has grown. The stakes are higher.

What has not kept pace is the quality of integrated thinking available to the people building dental businesses. There are more specialists than ever. There are fewer genuine integrators.

That is the gap Samera was built to fill.

Not by being the best accountant, or the best software company, or the best offshore provider – but by being the only firm in the sector that has built genuine capability across all of these domains simultaneously, held together by 25 years of accumulated context about how they actually connect.

The Medici family created the conditions for the Renaissance by putting the right disciplines in the same room. We have spent 25 years putting the right disciplines in the same firm.

The intersection is where the real problems live.

It is also where the real solutions come from.

Arun Mehra is the founder of Samera – a group spanning dental accounting, AI software, offshore delivery, commercial finance and European market entry – and co-founder of The Neem Tree Dental Group. He trained at PwC, worked as a VP at Bank of America, and has advised dental businesses across the UK for over two decades. Samera.ai is the intelligence layer connecting it all.


About the Author

Arun Mehra

Arun Mehra

With almost twenty years of commercial experience and knowledge in Dentistry, Arun’s expertise is valued by hundreds of businesses across the UK. His financial acumen and know-how, along with his hands-on commercial expertise have helped clients, large and small, new and established to achieve great things.

Arun is the founder of the Samera Group, starting the business with just one client sitting at his father’s dining table. Fifteen years on, Team Samera now service hundreds of Dental clients, run exciting events, help clients raise finance, and are very active in helping clients buy or sell Dental practices.


Bridgepoint Acquires MyDentist: What the £800m Deal Signals for Dental M&A in the UK

The UK dental sector has been a consistent target for private equity, with consolidators reshaping how practices grow and operate. In recent years, rising costs, staffing challenges, and a shift toward private care have changed how value is built and measured.

Now, with Bridgepoint’s re-entry into the sector through its acquisition of MyDentist, the market has received a strong signal about how private equity is currently valuing dental assets.

The deal, reportedly valued at around £800 million for a business generating £74 million in annual EBITDA across 600 practices, is notable not just for its size, but for what it suggests about current expectations around growth, value creation, and deal multiples.

In this article, we break down the deal’s key numbers, compare it with past transactions, and explore what it means for dental business owners across the UK, particularly those building toward a sale or looking to scale.

MyDentist: Key Financials and Deal Metrics

Here’s a snapshot of what’s publicly known about MyDentist’s financials:

  • Annual Revenue: ~£562 million
  • Annual EBITDA: ~£74 million
  • Number of Practices: ~600
  • Inferred EV/EBITDA Multiple: ~10x

This puts MyDentist’s acquisition firmly in the mid-range of typical private equity multiples. But when viewed in historical context, the current valuation sends a clear signal about changing market expectations.

Why the 10x Multiple Matters

The inferred 10x EV/EBITDA multiple paid by Bridgepoint for MyDentist is arguably the most instructive data point from this acquisition. It provides a clear reference for how the UK dental market is being valued today, particularly by large private equity firms.

In M&A terms, the EV/EBITDA multiple reflects what a buyer is willing to pay for a company’s earnings before interest, taxes, depreciation, and amortisation. 

For mature, cash-generative businesses like dental groups, this multiple is often used to benchmark deal pricing and future exit potential.

Historically, premium dental groups have fetched EBITDA multiples well above 12x, especially when:

  • Demand for dental assets was high,
  • Debt was cheap,
  • And consolidation opportunities were relatively untapped.

But a 10x multiple at this scale signals that even top-tier operators are now being valued with greater discipline. This has direct implications for dental operators across the market.

Downward Pressure on Smaller Group Valuations

Dental groups generating £1m–£5m in EBITDA cannot reasonably expect to attract multiples in that same range unless they bring something unique to the table. This could include:

  • A dominant private payor base
  • Specialised treatments (e.g., implants, ortho, cosmetic)
  • Highly efficient operations
  • Exceptional clinical leadership or brand reputation

Without these differentiators, buyers will apply a discount, often valuing such businesses at 5x–8x EBITDA depending on risk, growth, and integration potential.

More Emphasis on Margin and Operational Quality

It’s no longer sufficient to focus on gross revenue or the number of practices. Buyers are now scrutinising:

  • EBITDA margins (as a % of revenue)
  • Cost structures and headcount efficiency
  • Revenue per chair or per clinician
  • Private-to-NHS revenue mix
  • Level of digital maturity and tech stack efficiency

A smaller dental group might have £2m in revenue, but if margins are tight and cost discipline is weak, its value will be significantly lower than a leaner operation delivering £500k EBITDA off the same turnover.

Valuation Arbitrage Strategies Are Back in Focus

Private equity buyers like Bridgepoint rely on valuation arbitrage to generate returns. 

That means acquiring smaller businesses at lower EBITDA multiples (say, 5x–7x), integrating them into a larger group, and benefiting from the uplift when the group is valued collectively at a higher multiple (closer to 10x or more).

For vendors, the takeaway is this: unless you can grow EBITDA and demonstrate margin resilience before a sale, you’ll be priced as a bolt-on not as a platform.

Shift in Exit Planning Timelines

The new benchmark also affects exit timing. Many small-to-mid-sized group owners have built portfolios with the intention of exiting at double-digit multiples.

With 10x now considered top-of-market, some may delay exit plans to focus on margin improvement, digital enablement, and organic growth to make their business more attractive.

Alternatively, some may choose to exit sooner, accepting a lower multiple but securing a faster deal, particularly if market uncertainty persists.

Lenders and Valuers Will Adjust Expectations

It’s not just buyers who use EV/EBITDA multiples to assess risk, lenders, valuers, and insurers do too. A lower market benchmark means:

  • Lower lending limits for acquisition financing
  • More conservative business valuations during refinancing
  • Greater scrutiny on forecast assumptions in business plans

Operators who are over-leveraged or banking on high-multiple exits should reassess their financial models considering this new pricing environment.

Bridgepoint’s Likely Playbook: How They May Add Value

Based on past strategy and current market realities, Bridgepoint’s growth and value-creation plan is likely to focus on three key areas:

Buy Smaller Practices at Lower Multiples

To achieve outsized returns, Bridgepoint will likely pursue bolt-on acquisitions at significantly lower valuations – potentially in the 5x–7x range. This arbitrage strategy – buy low, scale up, and increase group EBITDA – is a proven method in private equity.

For smaller groups, this means that unless they have premium metrics (e.g., high-margin private dentistry, strong digital infrastructure, or specialist services), they are unlikely to fetch anything close to a 10x multiple.

Optimise Existing Operations

Cost reduction and operational efficiency will play a major role. Expect investments in:

  • Digital booking and triage systems
  • AI-based diagnostics and treatment planning
  • Centralised procurement and HR
  • Workforce optimisation to tackle clinical recruitment issues

Margins will be key. Bridgepoint will likely aim to raise EBITDA margins to drive value organically from the existing base.

Greenfield Expansion

Starting new practices in underserved or growth-potential locations may also be part of the strategy. These can be structured with better cost controls and optimised workflows from day one, boosting group performance over time.

What This Means for Smaller Dental Groups

For independent practice owners or small-to-mid-sized dental groups hoping to exit, this deal should serve as a wake-up call.

If a 600-practice group with £74 million EBITDA is being acquired at 10x, then smaller groups with £1m–£5m EBITDA are unlikely to command similar multiples unless they have a compelling differentiation story.

Buyers will be more selective, placing greater weight on:

  • Profitability (not just revenue)
  • Recurring private revenue
  • Operational efficiency
  • Scalability potential

Ultimately, groups seeking higher valuations need to focus on improving margins and creating operational value, not just growing top-line revenue or footprint.

Final Takeaways

Bridgepoint’s return to UK dentistry with the acquisition of MyDentist  signals confidence in the long-term fundamentals of dental healthcare while also establishing a new pricing reality for deals.

Dental group owners, investors, and operators should:

  • Benchmark their own EBITDA multiples realistically
  • Prioritise operational efficiency and margin expansion
  • Invest in digital and AI tools to remain competitive
  • Reassess growth strategies in light of current PE expectations

The landscape has changed and success in the next cycle will depend on how well businesses adapt to this new normal.

If your dental group is looking to grow, optimise, or prepare for a strategic sale, the right financial and operational guidance is critical. Get in touch with our team to explore tailored advisory solutions.

About the Author

Rajat Kumar

Rajat Kumar

Rajat is a finance and marketing professional with years of proven experience working in finance and investment KPOs.

Working with Samera’s business development experts, he specialises in creating tips, reports and articles helping accountants understand the global landscape, strategise and grow their business.

Reviewed By:

Arun Mehra

Arun Mehra
Samera CEO

Arun, CEO of Samera, is an experienced accountant and dental practice owner. He specialises in accountancy, financial directorship, squat practices and practice management.

Follow Arun on LinkedIn.

Samera Shortlisted for the Dental Industry Awards

We are (again) delighted to announce that we have been nominated for awards recognising excellence in the dental industry – this time in 4 categories! 

The Dental Industry Awards have shortlisted Samera in 4 categories, out of a record-breaking number of entries. 

Samera have been shortlisted to win awards for: 

  • Website of Year 
  • Dental Industry Event of the Year (Setting up in Practice Bootcamp)
  • Event of the Year (Setting up in Practice Bootcamp)
  • COVID-19 Response

We are immensely proud that our hard work over the last 1 or 2 has been recognised in the industry and we think this reflects the effort we have put in and all that we have accomplished for and with our clients. 

If you want to find out what makes Samera worthy of being award-nominated then contact us today or book a call with our team at a time that suits you.